HSBC Holdings’s Syndax Pharmaceuticals SNDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$556K Buy
23,461
+730
+3% +$15.9K ﹤0.01% 2179
2025
Q4
$482K Sell
22,731
-33,793
-60% -$590K ﹤0.01% 2337
2025
Q3
$884K Sell
56,524
-50,263
-47% -$658K ﹤0.01% 1847
2025
Q2
$966K Buy
106,787
+56,512
+112% +$622K ﹤0.01% 1822
2025
Q1
$613K Sell
50,275
-472
-0.9% -$6.66K ﹤0.01% 1984
2024
Q4
$656K Buy
50,747
+6,741
+15% +$115K ﹤0.01% 2019
2024
Q3
$852K Buy
44,006
+409
+0.9% +$8.45K ﹤0.01% 1768
2024
Q2
$884K Buy
43,597
+4,006
+10% +$83.8K ﹤0.01% 1729
2024
Q1
$942K Sell
39,591
-9,127
-19% -$204K ﹤0.01% 1803
2023
Q4
$1.05M Buy
+48,718
New +$749K ﹤0.01% 1740

Other funds holding SNDX

HSBC Holdings's SNDX Position: Q1 2026 in Review

HSBC Holdings increased its Syndax Pharmaceuticals (SNDX) stake by 3.2% in Q1 2026, buying an estimated $15.9K and bringing the position to 23,461 shares worth $556K. The position accounts for ﹤0.01% of the portfolio, ranked #2179.

HSBC Holdings first reported a position in SNDX in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.05M in Q4 2023. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • HSBC Holdings held 23,461 shares of Syndax Pharmaceuticals worth $556K as of Q1 2026.
  • HSBC Holdings bought 730 Syndax Pharmaceuticals shares in Q1 2026, an estimated $15.9K.
  • Syndax Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2179 holding.
  • HSBC Holdings first reported a position in Syndax Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • HSBC Holdings's Syndax Pharmaceuticals position peaked at $1.05M in Q4 2023.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.